BioCentury-BayHelix China Healthcare Summit - Award Winners
For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. In 2026, BayHelix and BioCentury will jointly host the BioCentury-BayHelix China Healthcare Summit (Nov. 2-4 at The St. Regis Shanghai Jingan), and will present the awards in six categories: R&D Achievement of the Year; M&A Deal of the Year; Licensing Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Woman Leader of the Year.
CONGRATULATIONS TO ALL THE 2026 AWARD WINNERS
2026 AWARD WINNERS
R&D Achievement of the Year | Abogen and Pregene
R&D Achievement of the year, recognizing a scientific discovery in China with direct impact to drug and/or MedTech R&D or a significant achievement in pharmaceutical and/or MedTech development milestones.
Abogen and Pregene
Two pioneering Chinese biotech companies advancing in vivo therapies.
➤ Abogen’s in vivo T-cell engager platform produced ABO2203, the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. Early data showed rapid, complete B-cell depletion with no cytokine release syndrome, and the platform attracted a Novartis deal worth $7.2B in milestones and royalties.
➤ Pregene was the first company to generate in vivo CAR efficacy data, an achievement that directly led to AstraZeneca’s acquisition of EsoBio, and its R&D capability was further validated by a $1.5B licensing partnership with Kite, including $120M in immediate payment.
These milestones showcase how frontier RNA innovation and China’s investigator-initiated trial framework are propelling Chinese biotech to the forefront of in vivo therapies.
M&A Deal of the Year | Avere Therapeutics and NextCure
M&A Deal of the year, recognizing a groundbreaking pharmaceutical and/or MedTech M&A or joint venture that involves a Chinese entity, either within China or cross-border.
Avere Therapeutics and NextCure
Avere, a newco formed by Hansoh Pharmaceutical to hold ex-Greater China rights to its once-weekly oral IL-23 receptor antagonist AVR-001, executed a reverse merger into Nasdaq-listed NextCure, paired with a $320M private placement led by Fairmount and Hansoh.
The transaction illustrates a distinctive, repeatable model for bringing China-originated innovation to global public markets.
M&A Deal of the Year | Biogen and TJ Biopharma
M&A Deal of the year, recognizing a groundbreaking pharmaceutical and/or MedTech M&A or joint venture that involves a Chinese entity, either within China or cross-border.
Biogen and TJ Biopharma
Biogen consolidated global rights to felzartamab by acquiring TJ Biopharma’s Greater China rights — a deal transcending conventional licensing. TJ Bio received $100 million upfront payment, for up to $850 million total consideration plus tiered royalties, and serves as the manufacturer for the multiple myeloma indication.
The deal highlights the evolving ways global biopharma is partnering with Chinese biotech.
Licensing Deal of the Year | Crescent Biopharma and Kelun-Biotech
Licensing Deal of the year, recognizing a transformative pharmaceutical and/or MedTech licensing, collaboration, or technology transfer agreement that involves a Chinese entity, either within China or cross-border.
Crescent Biopharma and Kelun-Biotech
This creative asset-for-asset partnership gives Crescent access to Kelun-Biotech’s innovative ADC program SKB105, while Kelun-Biotech obtains China rights to Crescent’s next-generation PD-1 x VEGF bispecific CR-001.
The highly synergistic structure positions both assets to be developed together and reflects a sophisticated dealmaking model for cross-border biopharma partnerships.
Licensing Deal of the Year | Merck and SciBrunch Therapeutics
Licensing Deal of the year, recognizing a transformative pharmaceutical and/or MedTech licensing, collaboration, or technology transfer agreement that involves a Chinese entity, either within China or cross-border.
Merck and SciBrunch Therapeutics
For $400M upfront, in an exclusive global license worth up to $2.13B, Merck secured worldwide rights to SciBrunch’s preclinical oral molecular-glue inhibitor of KRAS G12D (ON).
Striking for its size relative to a young biotech that has raised just $65M to date, the deal signals global pharma reaching into China’s preclinical innovation base well before proof-of-concept data.
Commercial Achievement of the Year | InnoCare Pharma
Commercial Achievement of the year, recognizing a creative model that delivered superior value to patients/payers in China and commercial success.
InnoCare Pharma
Drug sales grew 43.2% year-on-year to RMB 918.1M in the first half of 2026, driven by accelerating orelabrutinib sales following its NRDL inclusion, as the company turned a prior-year loss into a RMB 239.7M profit.
With the launch of the first CD19 antibody approved in China for relapsed/refractory DLBCL, InnoCare has demonstrated a durable, scalable commercialization model in China’s competitive biopharma landscape.
Commercial Achievement of the Year | HUTCHMED
Commercial Achievement of the year, recognizing a creative model that delivered superior value to patients/payers in China and commercial success.
HUTCHMED
Its key China products grew more than 40% in the first half of 2026, including ELUNATE (+41%) and SULANDA (+45%), fueled by expanded reimbursement and clinical adoption.
Company of the Year | Innovent Biologics
Company of the year, recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, MedTech and/or healthcare industry.
Innovent Biologics
Over the past ten months, strategic collaborations with Takeda, Eli Lilly and Pfizer have brought its partnered pipeline to 20+ assets with an aggregate deal value of roughly $34B.
Its mazdutide is the world’s first and only approved GCG/GLP-1 dual-receptor agonist, and Innovent also commercialized SYCUME, China’s first innovative thyroid eye disease therapy, and SINTBILO, the first China-domestic PCSK9 inhibitor on the NRDL—operating at full strength across dealmaking, R&D and commercial execution.
Woman Leader of the Year | Bihua Chen
Woman leader of the year: recognizing an outstanding female leader whose contributions have changed the landscape, reputation and ecosystem for biopharma or MedTech in China.
Bihua Chen, Founder of Cormorant Asset Management
Since 2013, she and her fund have recorded 40+ successful exits, including M&A exits of Synovation, RayzeBio and Prometheus, pre-IPO investments in Innovent Biologics and Zai Lab, and two SPACs that merged with MoonLake and BridgeBio Oncology.
A dedicated supporter of biotech entrepreneurs, especially women founders and CEOs, she exemplifies the investing acumen and commitment to the next generation of leaders shaping the global biotech industry.
2025 Winners
For a list of 2025’s winners, please visit the 2025 China Summit web page here.